Results 101 to 110 of about 1,651 (200)

Production, isolation, and shipment of clinically relevant quantities of astatine-211: A simple and efficient approach to increasing supply

, 2023
Lauren A. McIntosh, Jonathan D. Burns, E. E. Tereshatov, Riccardo Muzzioli, K. Hagel, Noimat Abeni Jinadu, Laura A. McCann, Gabriela A. Picayo, Federica Pisaneschi, David Piwnica‐Worms, Steven J. Schultz, G. Tăbăcaru, A. Abbott, Brooklyn D. Green, Travis Hankins, A. Hannaman, Bryan M. Harvey, Kylie Lofton, Robert L. Rider, Maxwell Sorensen, Alexandra Tabacaru, Zachary Tobin, S. J. Yennello   +22 more
openalex   +2 more sources

Automated Isolation of Astatine-211 and Chemistry Evaluation. Final report, June 1, 2017 through June 30, 2020

, 2020
D. Scott Wilbur
openalex   +2 more sources

標的アイソトープ治療に向けたアスタチン211イメージングのためのコンプトンカメラの開発 [PDF]

, 2019
Tohoku ...
Nagao Yuto
core   +1 more source

Development of PSMA-Targeted Alpha Therapy Using [²¹¹At]PSMA-5 [PDF]

Watabe T., Naka S., Shirakami Y., et al. Development of PSMA-Targeted Alpha Therapy Using [²¹¹At]PSMA-5. Seminars in Nuclear Medicine 55, 947 (2025); https://doi.org/10.1053/j.semnuclmed.2025.09.005.Astatine (²¹¹At) is an alpha-emitting nuclide with a 7 ...
Cardinale, Jens, Giesel, Frederik L., Kaneda, Kazuko, Murakami, Masashi, Naka, Sadahiro, Shirakami, Yoshifumi, Toyoshima, Atsushi, Watabe, Tadashi   +7 more
core   +1 more source

Abstracts

Cancer Science, Volume 117, Issue S1, Page 1-2148, January 2026.
wiley   +1 more source

Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine. [PDF]

Int J Mol Sci, 2023
Aso A, Nabetani H, Matsuura Y, Kadonaga Y, Shirakami Y, Watabe T, Yoshiya T, Mochizuki M, Ooe K, Kawakami A, Jinno N, Toyoshima A, Haba H, Wang Y, Cardinale J, Giesel FL, Shimoyama A, Kaneda-Nakashima K, Fukase K.   +18 more
europepmc   +1 more source

Development of Targeted Alpha Particle Therapy for Solid Tumors [PDF]

, 2019
: Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or small molecules that recognize tumor-associated antigens or cell ...
Budzevich, Mikalai M., Doligalski, Michael L., el-Haddad, Ghassan, Khushalani, Nikhil I., McLaughlin, Mark L., Moros, Eduardo G., Morse, David L., Pandya, Darpan N., Tafreshi, Narges K., Tichacek, Christopher J., Wadas, Thaddeus J.   +10 more
core   +1 more source

Simulation of the distribution of astatine-211 solution dispersion in a lab room. [PDF]

Nucl Med Commun, 2021
Kubo H, Takahashi K, Shimoyama S, Zhao S, Ukon N, Ito H.   +5 more
europepmc   +1 more source

Medical Radioisotopes Produced with Cyclotron Beams in Warsaw [PDF]

, 2017
The various production routes of the prospective medical radioisotopes 43Sc, 44gSc, 44mSc, 47Sc, 44Ti/44gSc, 99mTc, 72Se/72As and 211At were investigated by a team from the Heavy Ion Laboratory, University of Warsaw (HIL-UW), the University of Silesia (
Choiński, J., Jastrzębski, J., Napiorkowski, P. J., Sitarz, M., Stolarz, A., Szkliniarz, Katarzyna, Trzcińska, A., Wojtkowska, J., Zipper, Wiktor   +8 more
core  

Targeted alpha therapies using ²¹¹At:A Geant4 simulation of dose and DNA damage [PDF]

Introduction:Targeted alpha therapies show great potential for cancer treatment due to their high linear energy transfer (LET) and low range. 211At is currently employed in clinical trials.
Abu Sabah, Lujin H S, Ballisat, Laura, Beck, Lana M G, De Sio, Chiara, Duan, Jinyan, Guatelli, Susanna, Rosenfeld, Anatoly, Sakata, Dousatsu, Shi, Yuyao, Velthuis, Jaap J   +9 more
core   +1 more source